| Website | merus.nl |
| Category | BioTech |
| Phone | 31 655 764 221 |
| enquiries@merus.nl | |
| Employees | |
| Founded | 2003 |
| TOTAL | $30.3M |
| FUNDING TOTAL | $30.3M |
| Series B, 1/10 Novartis Venture Fund Pfizer Bay City Capital Life Sciences Partners | €21.7M |
Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.
